Last year's most important US False Claims Act story for the medical device industry was the continued repercussions and questions from a 2016 US Supreme Court decision, Universal Health Services Inc. v. United States ex rel. Escobar. The case changed the rules on when a company could be held liable for a false claim.
That’s according to Jonathan Phillips, a partner with Gibson Dunn, who discussed the law firm's 2017 Year-End False Claims Update with Medtech Insight.